Status:
COMPLETED
Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
Lead Sponsor:
Alcon Research
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study ...
Detailed Description
To evaluate the IOP lowering efficacy and safety fo Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The study structure is a parallel...
Eligibility Criteria
Inclusion
- ≥18 years;
- IOP=16-30mmHg
- OH or OAG with visual filed abnormality:
- ≥3 adjacent points in 24 degrees field on the same side of the horizontal meridian, that have p \<5% on the prepapillary diameter plot, one of which must have p \<1%,
- Glaucoma Hemifield Test outside normal limits,
- Corrected Pattern Standard Deviation with p \<5%
Exclusion
- Previous damage of anterior chamber angle;
- ocular inflammation or ocular surgery within the past 3 months; Best Corrected Visual Acuity (logMAR) \<1.0;
- contact lens wearer;
- severe central field loss;
- uncontrolled cardiovascular, hepatic or renal disease;
- any medication within past 1 month.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT00763061
Start Date
May 1 2006
End Date
April 1 2008
Last Update
March 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alcon Call Center
Fort Worth, Texas, United States, 76134